Accolade provides personalized health and benefits solutions that enhance employee engagement and optimize healthcare outcomes for employers. By leveraging data analytics and tailored support, the platform reduces healthcare costs while improving the overall employee experience.

Anda is a mobility technology platform in Angola that provides motorcycle taxi services, asset financing, and delivery solutions, utilizing GPS tracking and a rigorous driver training program to ensure safety and reliability. The platform addresses the lack of accessible and safe transportation options for underserved communities by offering affordable rides and empowering local entrepreneurs with tailored financial products.

E INC enhances the automotive purchasing process by providing a digital platform that streamlines wholesale and retail transactions through advanced technology and data analytics. This approach addresses inefficiencies in the automotive ecosystem, enabling faster and more flexible business operations for dealers and consumers.

Eve is a customizable AI assistant designed specifically for the legal profession, enabling attorneys to efficiently draft legal documents, analyze case data, and manage discovery processes. By automating time-consuming tasks, Eve allows law firms to handle more cases and improve their operational efficiency without increasing headcount.

Hang is a brand loyalty membership platform that utilizes AI-driven personalization and gamification to create tailored rewards and promotional campaigns across various customer touchpoints. By integrating with POS and CRM systems like Square and Shopify, Hang enhances customer engagement and retention for brands in sectors such as food and beverage, eCommerce, and retail.

Re is an on‑chain reinsurance protocol that tokenizes real reinsurance treaties, issuing fully collateralized tokens backed by verified insurance premiums. The platform provides institutional investors and insurers with regulated, transparent access to the $800B+ reinsurance market, delivering 8‑16% annual yields that are largely uncorrelated with traditional assets while maintaining defined risk limits and underwriting discipline.

Tr1X Inc. develops allogeneic engineered Tr1 Treg cell therapies to restore immune tolerance in patients with treatment-refractory autoimmune and inflammatory diseases, such as Crohn’s disease. Their proprietary platform generates stable, long-lived regulatory T cells that modulate immune responses and induce de-novo Tr1 cells at sites of inflammation.